California State Teachers Retirement System decreased its stake in shares of Trovagene Inc. (NASDAQ:TROV) by 6.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,077 shares of the company’s stock after selling 4,358 shares during the period. California State Teachers Retirement System owned approximately 0.20% of Trovagene worth $268,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. State Street Corp increased its stake in Trovagene by 21.3% in the first quarter. State Street Corp now owns 390,759 shares of the company’s stock valued at $1,819,000 after buying an additional 68,557 shares in the last quarter. Geode Capital Management LLC increased its stake in Trovagene by 1.3% in the first quarter. Geode Capital Management LLC now owns 183,442 shares of the company’s stock valued at $853,000 after buying an additional 2,363 shares in the last quarter. Bridger Management LLC bought a new stake in Trovagene during the first quarter valued at approximately $15,301,000. Finally, Princeton Capital Management Inc. bought a new stake in Trovagene during the second quarter valued at approximately $314,000. 31.05% of the stock is owned by hedge funds and other institutional investors.
Trovagene Inc. (NASDAQ:TROV) traded down 1.18% during midday trading on Wednesday, hitting $4.20. The company had a trading volume of 8,768 shares. The company’s 50 day moving average is $4.65 and its 200 day moving average is $4.88. Trovagene Inc. has a 12-month low of $2.85 and a 12-month high of $7.18. The stock’s market cap is $126.62 million.
Trovagene (NASDAQ:TROV) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.03. Trovagene had a negative return on equity of 80.13% and a negative net margin of 8,495.00%. On average, equities analysts anticipate that Trovagene Inc. will post ($1.34) EPS for the current fiscal year.
Several equities analysts have issued reports on the company. Maxim Group assumed coverage on Trovagene in a research report on Wednesday, July 6th. They set a “buy” rating and a $12.00 target price on the stock. Zacks Investment Research upgraded Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Piper Jaffray Cos. set a $4.00 target price on Trovagene and gave the stock a “hold” rating in a research report on Friday, August 5th. Finally, Cantor Fitzgerald upgraded Trovagene from a “hold” rating to a “buy” rating and boosted their target price for the stock from $5.00 to $7.00 in a research report on Monday, August 8th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Trovagene presently has an average rating of “Hold” and an average price target of $6.54.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Want to see what other hedge funds are holding TROV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trovagene Inc. (NASDAQ:TROV).
Receive News & Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.